It will be vital for providers of healthcare to consider whether innovations truly improve people’s lives and make care more efficient, or will they just be another layer on the workflow and take clinicians’ time away from patients.
Healthcare HR professionals—if they haven’t already—must reshape the workplace each and every day by focusing intently and with new eyes on what matters most during this ongoing pandemic: employees.
In a 10-year study in patients vaccinated with Gardasil 9, no cases of HPV-related cancers or genital warts were seen.
Crisis tests a business's culture. It also is a good time to create or strengthen a culture.
In order to navigate the new landscape COVID-19 has brought along with it and connect with consumers who may be feeling confused and stressed out, lesser-known health insurers will need to introduce themselves to this new audience.
Sharing technologies like blockchain could help healthcare institutions establish a consistent, accurate, and trustworthy approach to data collection and dissemination.
The growth of digital twin technology — paired with the transition towards personalized medicine — has left many healthcare industry professionals evaluating the potential of a “patient twin.”
Medical debt can send people into “a spiral of economic disadvantage,” including a lack of stability and security in personal life, housing and work.
The ‘payvider’ model is best suited for health systems that want to double down on value-based care.
Doing more to incorporate caregiver burden into value assessments and cost-effectiveness research of Duchene muscular dystrophy treatments was the focus of a recent International Society for Pharmacoeconomics and Outcomes Research (ISPOR) webinar.
A reduction in emergency room visits is just one of the ways teledermatology has improved patient outcomes and reduced costs, according to Elizabeth K. Jones, M.D., an associate dermatology professor at Thomas Jefferson University Hospital in Philadelphia.
COVID-19 sped up healthcare’s digital transformation. The 20-minute telehealth visit can mean less unpaid time off from work and the difference between seeking care and putting food on the table. Care-at-home programs can reduce the risks associated with hospitalization, such as hospital-acquired infections.
Five years ago, health care providers didn’t see mobile as a priority or a necessary tool in improving the patient experience. The pandemic changed that.
Drs Steven Levine, Patricia Ares-Romero, Samuel Nordberg, Martin Rosenzweig, and Carrie Jardine share insight on the future treatment landscape for TRD.
As payer and provider organizations look to improve health outcomes around the far-reaching impacts of the pandemic, they must consider the unique needs of some of our most vulnerable populations, such as new and expecting mothers and their infants.
An expert in the field of rheumatology predicts how the treatment landscape will evolve for intravenous and subcutaneous therapies.
Enterprise imaging platforms would enable organizations to consistently and optimally capture, index, manage, store, distribute, view, exchange and analyze all clinical imaging and multimedia content, enhancing patients’ electronic health records.
Novo Nordisk said it’s open to discussions with PBMs based on their commitments that a lower semgalutide list price would not impact formulary coverage.
A future where healthcare may include augmented reality, robots and drones may be more fact than fiction, says George Van Antwerp, SVP of product innovation and strategic planning at Prime Therapeutics.
Predictions for 2025 by Tracy Baroni Allmon, J.D., vice president of Market Access and Policy at Magnolia Market Access.
Panelists discuss how, as new data on cemiplimab and other checkpoint inhibitors emerge, the treatment pathway for cancers like non-small cell lung cancer (NSCLC) is expected to evolve toward more personalized, targeted approaches. This will enhance survival outcomes, refine patient selection and optimize therapy regimens.
Due to one of the most challenging global crises in living memory and one that presented an acute challenge for the medical community, healthcare providers find themselves operating within an uncertain landscape. They are still managing the fallout of COVID-19 while also planning for the future.
Pharmacogenomics looks at how genetic influences affect an individual’s response to therapeutic medications.
The delivery of care model needs to scale across the community settings while servicing the unique needs of each patient.
Recent study finds that Medicaid coverage for some of the first gene and cell therapies was at times delayed and not consistent with federal requirements.
Identifying the right payer before a healthcare service is provided and billing on time, reduces costs, prevents bad debt and maximizes reimbursements and revenue.
Organizations setting up hospital-at-home programs need to be aware of the associated risks and mitigation best practices.